FLT3 and acute myeloid leukemia: Recently, Jahn et al. reported that midostaurin might improve OS and DFS of FLT3-mutated AML patients with chromatin-spliceosome mutations.29 Smith et al. reported that gilteritinib might improve OS in FLT3-mutated patients carrying mutated DNA methylation/hydroxymethylation mutations, while it did not improve the outcome of those with mutated RTK/Ras signaling genes.28 In this study, we found that the patients with “activated signaling” and “DNA methylation” mutations might benefit from sorafenib.